Roger Pebody is the managing editor at NAM, a nonprofit organization in the United Kingdom that publishes news, information, and educational materials about HIV. He runs the day-to-day content operations at aidsmap, NAM's flagship site, for which he has worked since 2008.
The uptake of pre-exposure prophylaxis (PrEP) has been highly skewed, with some people who need PrEP the most being less likely to get it.
A Dutch cohort study of men who have sex with men (MSM) over the age of 45 finds that HIV infection and lopinavir/ritonavir use each are independently associated with decreased erectile function.
The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).
For HIV-positive men with osteopenia, bisphosphonate therapy with zoledronic acid is more effective at increasing bone mineral density than switching from tenofovir disoproxil fumarate (TDF, Viread).
Key next steps in providing PrEP are:
Discuss PrEP with your patient.
Ask what he or she is currently doing to protect themselves from HIV. Discuss the benefits and risks of PrEP.
Identify insurance or other reimbursement for your patient.
There's a big difference between 7 days and 20 days. Listen in as researchers and providers hash out the data, and what to tell those who need the information the most.
There is a significant "statin treatment gap" for people living with HIV, with only 47% of people eligible for statins receiving them in 2013, according to a recent study.
Due to the impact of the Affordable Care Act (ACA), in just two years the proportion of people living with HIV in care covered by Medicaid increased from 36% to 42% and the proportion that were uninsured fell from 18% to 14%.